Antisense cancer therapy: the state of the science (Q34107762)

31 July 2017

1 reference

title

Antisense cancer therapy: the state of the science (English)

1 reference

31 July 2017

Kushner DM

1

1 reference

31 July 2017

Silverman RH

series ordinal

2

1 reference

31 July 2017

publication date

1 January 2000

1 reference

31 July 2017

published in

Current Oncology Reports

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

23-30

1 reference

The role of Myb proteins in normal and neoplastic cell proliferation

31 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-000-0007-Y

Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-000-0007-Y

An overview of progress in antisense therapeutics

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-000-0007-Y

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

21 January 2018

1 reference

12 December 2020

In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides

1 reference

12 December 2020

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

12 December 2020

A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA.

1 reference

12 December 2020

Protein kinase C: structure, function, and regulation

1 reference

12 December 2020

Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies

1 reference

12 December 2020

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

1 reference

12 December 2020

In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation

1 reference

12 December 2020

The therapeutic potential of ribozymes

1 reference

12 December 2020

Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha

1 reference

12 December 2020

First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies.

1 reference

12 December 2020

Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide

1 reference

12 December 2020

Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression

1 reference

12 December 2020

Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera

1 reference

12 December 2020

Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides

1 reference

12 December 2020

bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs

1 reference

12 December 2020

p53 in hematologic malignancies.

1 reference

12 December 2020

Antisense therapeutics

1 reference

12 December 2020

Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide

1 reference

12 December 2020

Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial

1 reference

12 December 2020

Discrimination between ribonuclease H- and ribonuclease L-mediated RNA degradation by 2'-O-methylated 2-5A-antisense oligonucleotides

1 reference

12 December 2020

Nucleic acid therapeutics: state of the art and future prospects.

1 reference

12 December 2020

Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide

1 reference

12 December 2020

Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences.

1 reference

12 December 2020

Application of preformed hammerhead ribozymes in the gene therapy of cancer (review).

1 reference

12 December 2020

Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides

1 reference

12 December 2020

2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.

1 reference

12 December 2020

Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance.

1 reference

12 December 2020

Controlling gene expression with 2-5A antisense

1 reference

12 December 2020

Antisense comes of age

1 reference

12 December 2020

2,5-oligoadenylate-peptide nucleic acids (2-5A-PNAs) activate RNase L.

1 reference

12 December 2020

Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA.

1 reference

12 December 2020

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

12 December 2020

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

12 December 2020

c-myb and growth control

1 reference

12 December 2020

Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.

1 reference

12 December 2020

Double identity for proteins of the Bcl-2 family

1 reference

12 December 2020

Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides

1 reference

12 December 2020

Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C

1 reference

12 December 2020

Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome

1 reference

12 December 2020

Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides

1 reference

12 December 2020

In vitro and in vivo activity of antisense inhibitors of ras: potential for clinical development

1 reference

12 December 2020

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

1 reference

12 December 2020

Expression cloning of 2-5A-dependent RNAase: A uniquely regulated mediator of interferon action

1 reference

12 December 2020

Antisense oligonucleotides as therapeutics for malignant diseases.

1 reference

12 December 2020

Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics

1 reference

12 December 2020

10.1007/S11912-000-0007-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1051282556

0 references

1 reference